What should I avoid while taking Droxidopa 300mg capsules?

Take with or without food. Take consistently with regard to food. (Source: DrugBank, licensed under CC BY-NC 4.0)

Do I need a prescription for Droxidopa 300mg capsules?

Droxidopa 300mg capsules is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Droxidopa 300mg capsules?

Droxidopa 300mg capsules is the generic name. It is available under brand names including: Northera 300mg capsules. (Source: NHS dm+d — Actual Medicinal Products)

Droxidopa 300mg capsules

Prescription only

Requires a prescription from a doctor or prescriber

Capsule

300mg

Oral

Droxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism.

Active ingredients:

Droxidopa

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 02.07.02

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC C01CA27

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Droxidopa

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Browse all Drug Analysis Profiles A–Z

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

Search EudraVigilance database

Browse substances A–Z in the European adverse reaction database

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

1 branded products available

1 productsShow details

1 products

Possibly available on the UK marketRestricted supplyDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Droxidopa on the MHRA register

Northera 300mg capsules

Imported (United States)

None

Imported

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Therapeutically similar medicines

10 similarShow details

Adrenaline (base) 2mg/100microlitres nasal spray unit dose

Spray

2mg

Same therapeutic group

Isoprenaline hydrochloride 200micrograms/1ml solution for infusion ampoules

Infusion

1ml

Same therapeutic group

Noradrenaline (base) 250micrograms/50ml solution for injection vials

Injection

50ml

Same therapeutic group

Isoprenaline hydrochloride 1mg/5ml solution for infusion ampoules

Infusion

1mg/5ml

Same therapeutic group

Dopamine 45mg/30ml solution for infusion vials

Infusion

45mg/30ml

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Droxidopa

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Droxidopa

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

42755211000001106

dm+d ID

42755211000001106

VTM (Virtual Therapeutic Moiety)

775711004

VMP (Virtual Medicinal Product)

42755211000001106

BNF code

02070200

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

C01CA27

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

None known

Half-life

2-3 hours

Mechanism

Droxidopa crosses the blood-brain barrier where it is converted to norepinephrin…

Food interactions

1 warning

Human targets

10 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

90%

Oral bioavailability is 90%.

Half-life

2-3 hours

2-3 hours.

Metabolism

Droxidopa is metabolized by aromatic L-amino acid decarboxylase.

Elimination

Droxidopa is mainly excreted in the urine, with the main metabolite being 3-O-methyldihydroxyphenylserine.

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

Droxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism. It is approved for use in Japan and is currently in trials in the U.S. The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a deficit of noradrenaline as well as of dopamine in Parkinson's disease and it has been proposed that this underlies the sudden transient freezing seen usually in advanced disease.

Though L-DOPS has been used in Japan and Southeast Asia already for some time, it is also currently in clinical trials at the phase III point in the United States (U.S.), Canada, Australia, and throughout Europe. Provided L-DOPS successfully completes clinical trials, it could be approved for the treatment of neurogenic orthostatic hypotension (NOH) as early as 2011. Additionally, phase II clinical trials for intradialytic hypotension are also underway. Chelsea Therapeutics obtained orphan drug status (ODS) for L-DOPS in the U.S. for NOH, and that of which associated with Parkinson's disease , pure autonomic failure, and multiple system atrophy, and is the pharmaceutical company developing it in that country.

Properties:

solid

Avg. mass: 213.19 Da

DrugBank indication

For treatment of neurogenic orthostatic hypotension (NOH) associated with various disorders including Multiple System Atrophy, Familial Amyloid Polyneuropathy, hemodialysis induced hypotension and Parkinson's Disease. Also investigated for use/treatment in neurologic disorders, nephropathy, blood (blood forming organ disorders, unspecified), and dizzy/fainting spells.

Also known as(66)

DOPS

Droxidopa

L-Dihydroxyphenylserine

L-DOPS

L-threo-dihydroxyphenylserine

ADRA1C

Alpha-1A adrenoceptor

Alpha-1A adrenoreceptor

Dosage forms(7)

Capsule (Oral) — 100 ug/1

Capsule (Oral) — 200 ug/1

Capsule (Oral) — 300 ug/1

Capsule (Oral) — 100 mg/1

Capsule (Oral) — 200 mg/1

Capsule (Oral) — 300 mg/1

Capsule, coated (Oral) — 300 mg

Molecular properties(19)

Drug interactions(1349)

Known interactions with other medications. Always consult a healthcare professional.

Valsartan

Moderate

DB00177

Droxidopa may decrease the antihypertensive activities of Valsartan.

Droxidopa 300mg capsules

Safety & regulatory

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science13

Chemical identifiers

Droxidopa

Additional database identifiers

DrugBank citations

Deep science
13